Parameter | Estimate | CV% | LLCI-ULCI |
---|---|---|---|
L-DOPA | Â | Â | Â |
Cl (mL/min) | 30 | 21 | 17 - 43 |
ω2 Cl | 0.26 | 59 | -0.041 - 0.56 |
V1 (mL) | 98 | 39 | 24 - 172 |
V2 (mL) | 157 | 15 | 112 - 202 |
V3 (mL) | 599 | 15 | 425 - 773 |
V4 (mL) | 13300 | 25 | 6810 - 19800 |
ω2 V4 | 0.075 | 40 | 0.020 - 0.13 |
Q2 (mL/min) | 22 | 24 | 11 - 32 |
Q3 (mL/min) | 11 | 16 | 7.5 - 15 |
Q4 (mL/min) | 22 | 14 | 16 - 29 |
Kin (min-1) | 5.8 | 36 | 1.7 - 9.8 |
ω2 Kin | 0.94 | 41 | 0.19 - 1.7 |
Proportional error (plasma) | 0.087 | 15 | 0.061 - 0.113 |
Proportional error (ECF) | 0.17 | 21 | 0.10 - 0.24 |
Control cerebral hemisphere | Â | Â | Â |
DOPAC | Â | Â | Â |
Formation k46 (min-1) | 0.000044 | 28 | 0.000020 - 0.000068 |
ω2 k46 | 0.50 | 60 | -0.084 - 1.1 |
k40 (min-1) | 0.53 | 23 | 0.29 - 0.77 |
ω2 k40 | 0.42 | 46 | 0.045 - 0.80 |
Elimination k60 (min-1) | 0.0053 | 17 | 0.0035 - 0.0071 |
ω2 k60 | 0.19 | 58 | -0.025 - 0.41 |
Residual error (additive) | 0.0020 | 16 | 0.0014 - 0.0026 |
HVA | Â | Â | Â |
Formation k47 (min-1) | 0.000023 | 15 | 0.000016 - 0.000030 |
ω2 k47 | 0.019 | 70 | -0.0070 - 0.000030 |
k40 (min-1) | 0.19 | 16 | 0.13 - 0.25 |
k70 (min-1) | 0.0044 | 12 | 0.0033 - 0.0054 |
ω2 k70 | 0.14 | 53 | -0.006 - 0.28 |
Residual error (additive) | 0.0028 | 24 | 0.0015 - 0.0041 |
Rotenone-treated responder cerebral hemisphere | Â | Â | |
DOPAC | Â | Â | Â |
Formation k58(min-1) | 0.000054 | 51 | -0.00000039 - 0.000011 |
ω2 k58 | 1.0 | 40 | 0.23 - 1.9 |
k50 (min-1) | 0.36 | 55 | -0.025 - 0.75 |
ω2 k50 | 0.53 | 36 | 0.16 - 0.90 |
Elimination k80 (min-1) | 0.038 | 18 | 0.024 - 0.052 |
Residual error (additive) | 0.0014 | 51 | 0.0000020 - 0.0027 |
HVA | Â | Â | Â |
Formation k59(min-1) | 0.000016 | 42 | 0.0000028 - 0.000030 |
ω2 k59 | 0.49 | 65 | -0.14 - 1.12 |
k50(min-1) | 0.14 | 55 | -0.010 - 0.29 |
Elimination k90 (min-1) | 0.011 | 39 | 0.0027 - 0.020 |
Residual error (additive) | 0.0034 | 41 | 0.00060 - 0.0061 |